Mario Delgado
#159,881
Most Influential Person Now
Researcher
Mario Delgado's AcademicInfluence.com Rankings
Mario Delgadocomputer-science Degrees
Computer Science
#9087
World Rank
#9547
Historical Rank
Computational Linguistics
#2141
World Rank
#2163
Historical Rank
Machine Learning
#3894
World Rank
#3940
Historical Rank
Artificial Intelligence
#4223
World Rank
#4281
Historical Rank
Download Badge
Computer Science
Mario Delgado's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Mario Delgado Influential?
(Suggest an Edit or Addition)Mario Delgado's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis (2009) (604)
- Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. (2009) (602)
- Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. (2009) (481)
- The Significance of Vasoactive Intestinal Peptide in Immunomodulation (2004) (408)
- Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis (2009) (403)
- Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease (2001) (388)
- Therapeutic action of ghrelin in a mouse model of colitis. (2006) (251)
- Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. (2003) (249)
- Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. (2009) (246)
- Regulation of immune tolerance by anti-inflammatory neuropeptides (2007) (226)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. (1999) (207)
- Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice (2012) (199)
- Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activation Polypeptide (PACAP) Protect Mice from Lethal Endotoxemia Through the Inhibition of TNF-α and IL-6 (1999) (198)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun* (1998) (192)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. (1999) (180)
- Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis (2012) (180)
- VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells (1999) (177)
- Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases (2001) (167)
- Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. (2005) (164)
- Immunology of VIP: a review and therapeutical perspectives. (2000) (162)
- Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide modulate endotoxin‐induced IL‐6 production by murine peritoneal macrophages (1998) (162)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. (1999) (161)
- Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation (2003) (159)
- Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. (2006) (158)
- Cell Senescence Abrogates the Therapeutic Potential of Human Mesenchymal Stem Cells in the Lethal Endotoxemia Model (2014) (149)
- Ghrelin Protects against Experimental Sepsis by Inhibiting High-Mobility Group Box 1 Release and by Killing Bacteria12 (2008) (144)
- Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. (2010) (142)
- The Neuropeptide Vasoactive Intestinal Peptide Generates Tolerogenic Dendritic Cells1 (2005) (142)
- Expression of the Mel1a‐melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen (1997) (140)
- Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. (2002) (137)
- Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions (2013) (136)
- Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit the production of inflammatory mediators by activated microglia (2003) (134)
- Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit chemokine production in activated microglia (2002) (130)
- Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes (1996) (124)
- Vasoactive intestinal peptide prevents activated microglia‐induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma (2003) (124)
- Enrichment of Human ESC‐Derived Multipotent Mesenchymal Stem Cells with Immunosuppressive and Anti‐Inflammatory Properties Capable to Protect Against Experimental Inflammatory Bowel Disease (2011) (123)
- PACAP in Immunity and Inflammation (2003) (121)
- Regulation of VIP production and secretion by murine lymphocytes (1999) (118)
- Immunobiology of vasoactive intestinal peptide (VIP) (2000) (114)
- Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia (2006) (114)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Interleukin-12 Transcription by Regulating Nuclear Factor κB and Ets Activation* (1999) (110)
- Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor (2002) (110)
- VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells (2004) (108)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Nuclear Factor-κB-dependent Gene Activation at Multiple Levels in the Human Monocytic Cell Line THP-1* (2001) (106)
- Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. (2006) (105)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. (1999) (104)
- Anti-inflammatory neuropeptides: A new class of endogenous immunoregulatory agents (2008) (104)
- Cutting Edge: Is Vasoactive Intestinal Peptide a Type 2 Cytokine? (2001) (104)
- Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. (2006) (103)
- Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn’s disease (2006) (102)
- Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. (2006) (100)
- Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. (2006) (96)
- VIP modulation of immune cell functions. (1996) (95)
- The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? (2004) (95)
- Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. (2006) (92)
- VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4+ T cells (2004) (90)
- Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. (2006) (89)
- Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo (2005) (88)
- Glial Innate Immunity Generated by Non-Aggregated Alpha-Synuclein in Mouse: Differences between Wild-type and Parkinson's Disease-Linked Mutants (2010) (88)
- Anti‐inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock (2000) (88)
- Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis (2006) (86)
- Inhibition of IFN-γ-Induced Janus Kinase-1-STAT1 Activation in Macrophages by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide (2000) (84)
- Human amnion favours tissue repair by inducing the M1‐to‐M2 switch and enhancing M2 macrophage features (2016) (84)
- Vasoactive intestinal peptide protects against β‐amyloid‐induced neurodegeneration by inhibiting microglia activation at multiple levels (2008) (84)
- Preconditioning of Microglia by α-Synuclein Strongly Affects the Response Induced by Toll-like Receptor (TLR) Stimulation (2013) (82)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Expression of Fas Ligand in Activated T Lymphocytes by Regulating c-Myc, NF-κB, NF-AT, and Early Growth Factors 2/31 (2001) (82)
- Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death (2009) (81)
- Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. (1997) (80)
- VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies 1 The first two authors have contributed equally to the present work. 1 (1998) (79)
- Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. (2008) (79)
- VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. (1999) (77)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. (1996) (76)
- Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. (2003) (74)
- Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. (2007) (74)
- Inhibition of Endotoxin-Induced Macrophage Chemokine Production by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide In Vitro and In Vivo1 (2001) (73)
- VIP and PACAP38 Modulate Cytokine and Nitric Oxide Production in Peritoneal Macrophages and Macrophage Cell Lines (1999) (73)
- Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses (2006) (72)
- Therapeutic Effect of Human Amniotic Membrane–Derived Cells on Experimental Arthritis and Other Inflammatory Disorders (2014) (72)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptides (PACAP27) and PACAP38) protect CD4+CD8+ thymocytes from glucocorticoid-induced apoptosis. (1996) (72)
- miR‐335 Correlates with Senescence/Aging in Human Mesenchymal Stem Cells and Inhibits Their Therapeutic Actions Through Inhibition of AP‐1 Activity (2014) (71)
- Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. (2007) (71)
- Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide promote in vivo generation of memory Th2 cells (2002) (70)
- Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. (2007) (70)
- Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages (1996) (70)
- Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. (2010) (67)
- Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. (1999) (66)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity. (2003) (66)
- Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. (1996) (61)
- Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells. (2007) (61)
- In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. (2008) (59)
- VIP: a very important peptide in T helper differentiation. (2003) (59)
- Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes (1994) (58)
- Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP. (2001) (56)
- Immunotherapy for neurological diseases. (2008) (55)
- Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Collagen-Induced Arthritis: An Experimental Immunomodulatory Therapy1 (2001) (54)
- Granzyme B, a New Player in Activation-Induced Cell Death, Is Down-Regulated by Vasoactive Intestinal Peptide in Th2 but Not Th1 Effectors1 (2006) (54)
- Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. (2008) (53)
- Cortistatin Inhibits Migration and Proliferation of Human Vascular Smooth Muscle Cells and Decreases Neointimal Formation on Carotid Artery Ligation (2013) (53)
- A Reduction in the Amount and Anti-Contractile Effect of Periadventitial Mesenteric Adipose Tissue Precedes Hypertension Development in Spontaneously Hypertensive Rats (2008) (53)
- Gene expression of VIP receptor in rat lymphocytes. (1994) (52)
- Pituitary adenylate cyclase-activating polypeptides ( PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes: comparison with VIP and implication of cAMP (1995) (52)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. (2002) (51)
- VIP Gene Expression in Rat Thymus and Spleen (1993) (50)
- Synthesis and Structure−Activity Relationships of a New Model of Arylpiperazines. 8.1 Computational Simulation of Ligand−Receptor Interaction of 5-HT1AR Agonists with Selectivity over α1-Adrenoceptors (2005) (49)
- Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA (1996) (49)
- Vasoactive intestinal peptide modulation of adherence and mobility in rat peritoneal lymphocytes and macrophages (1994) (48)
- Pituitary Adenylate-Cyclase-Activating Polypeptide Expression in the Immune System (2002) (48)
- Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy (2007) (48)
- Differential VIP and VIP1 receptor gene expression in rat thymocyte subsets (1996) (48)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia. (2002) (47)
- Vasoactive Intestinal Peptide Generates CD4+CD25+ Regulatory T Cells in vivo (2006) (47)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Antigen-Induced Apoptosis of Mature T Lymphocytes by Inhibiting Fas Ligand Expression1 (2000) (47)
- Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages (2000) (46)
- Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases. (2018) (46)
- Inhibition of Endotoxin-Induced Macrophage Chemokine Production by VIP and PACAP In Vitro and In Vivo (2001) (46)
- Role of vasoactive intestinal peptide in inflammation and autoimmunity. (2005) (46)
- Longitudinal studies of ischemic penumbra by using 18F-FDG PET and MRI techniques in permanent and transient focal cerebral ischemia in rats (2011) (45)
- Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? (2007) (45)
- Pituitary adenylate cyclase-activating polypeptide (PACAP38) modulates lymphocyte and macrophage functions: stimulation of adherence and opposite effect on mobility (1996) (45)
- VIP and PACAP Inhibit Activation Induced Apoptosis in T Lymphocytes (2000) (44)
- Vasoactive intestinal peptide inhibits cycloxygenase-2 expression in activated macrophages, microglia, and dendritic cells (2008) (44)
- N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. (2008) (43)
- Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis (2013) (43)
- Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response (2007) (43)
- VIP and PACAP Induce Shift to a Th2 Response by Upregulating B7.2 Expression (2000) (42)
- Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide (1999) (41)
- Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson's Disease. (2013) (41)
- Allogeneic Adipose-Derived Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Regulating Self-Reactive T Cell Responses and Dendritic Cell Function (2017) (40)
- Polymorphisms within the promoter and the intron 2 of the serotonin transporter gene in a population of bulimic patients (2003) (40)
- Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat (1994) (40)
- Mesenchymal stem cells induce the ramification of microglia via the small RhoGTPases Cdc42 and Rac1 (2014) (40)
- Therapeutic Efficacy of Stable Analogues of Vasoactive Intestinal Peptide against Pathogens* (2014) (38)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. (2001) (37)
- Vasoactive Intestinal Peptide in Thymus: Synthesis, Receptors and Biological Actions (1999) (37)
- Inhibitory neuropeptide receptors on macrophages. (2001) (37)
- The neuropeptides VIP/PACAP and T cells: inhibitors or activators? (2003) (37)
- Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. (2003) (36)
- Stimulation by vasoactive intestinal peptide (VIP) of phagocytic function in rat macrophages. Protein kinase C involvement (1993) (36)
- Regulation of Dendritic Cell Differentiation by Vasoactive Intestinal Peptide (2006) (36)
- Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease (2014) (36)
- Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. (2003) (35)
- Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions (2006) (35)
- Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors (2006) (34)
- Tuning immune tolerance with vasoactive intestinal peptide: A new therapeutic approach for immune disorders (2007) (34)
- Vasoactive intestinal peptide (VIP) inhibits TGF-β1 production in murine macrophages (2000) (33)
- Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP-38) Stimulates Rat Peritoneal Macrophage Functions (1996) (33)
- Analysis of a GT microsatellite in the promoter of the foxp3/scurfin gene in autoimmune diseases. (2005) (33)
- Human Bone Marrow Stromal Cells Lose Immunosuppressive and Anti-inflammatory Properties upon Oncogenic Transformation (2014) (33)
- Neuropeptides: keeping the balance between pathogen immunity and immune tolerance. (2010) (32)
- Statistical parametric maps of 18F-FDG PET and 3-D autoradiography in the rat brain: a cross-validation study (2011) (32)
- Peripheral Nerve Repair Through Multi-Luminal Biosynthetic Implants (2011) (31)
- VIP Prevents Experimental Multiple Sclerosis by Downregulating Both Inflammatory and Autoimmune Components of the Disease (2006) (31)
- Protective Role for Plasmid DNA‐Mediated VIP Gene Transfer in Non‐Obese Diabetic Mice (2006) (30)
- TH2 Lymphocytes Secrete Functional VIP upon Antigen Stimulation (2001) (30)
- Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders (2008) (30)
- Mice with Decreased Cerebral Dopamine Function following a Neurotoxic Dose of MDMA (3,4-Methylenedioxymethamphetamine, “Ecstasy”) Exhibit Increased Ethanol Consumption and Preference (2007) (29)
- A Novel Mechanism for Immunosuppression: from Neuropeptides to Regulatory T Cells (2006) (29)
- Analysis of trans-resveratrol by laser ionization mass spectrometry and HPLC with fluorescence detection. Comparison between both techniques. (2005) (28)
- Vasoactive Intestinal Peptide (2006) (28)
- Cortistatin attenuates inflammatory pain via spinal and peripheral actions (2014) (27)
- Specific calcineurin targeting in macrophages confers resistance to inflammation via MKP‐1 and p38 (2014) (26)
- Analgesic effect of the neuropeptide cortistatin in murine models of arthritic inflammatory pain. (2013) (26)
- Initial performance evaluation of a high resolution Albira small animal positron emission tomography scanner with monolithic crystals and depth-of-interaction encoding from a user's perspective (2009) (26)
- Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats (2015) (25)
- Changes in NPY and POMC, but not serotonin transporter, following a restricted feeding/repletion protocol in rats (2010) (25)
- Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders (2008) (24)
- LABCG2, a New ABC Transporter Implicated in Phosphatidylserine Exposure, Is Involved in the Infectivity and Pathogenicity of Leishmania (2013) (24)
- Tuning inflammation with anti-inflammatory neuropeptides (2007) (24)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit T Cell-Mediated Cytotoxicity by Inhibiting Fas Ligand Expression1 (2000) (23)
- Generating tolerogenic dendritic cells with neuropeptides. (2009) (22)
- Cortistatin reduces atherosclerosis in hyperlipidemic ApoE-deficient mice and the formation of foam cells (2017) (22)
- Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA. (2004) (22)
- Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells. (2008) (22)
- Vasoactive Intestinal Peptide Ameliorates Acute Myocarditis and Atherosclerosis by Regulating Inflammatory and Autoimmune Responses (2018) (21)
- Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease (2017) (21)
- Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease (2017) (21)
- Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: A longitudinal in-vivo study (2015) (21)
- Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors. (2005) (21)
- Metyrapone prevents brain damage induced by status epilepticus in the rat lithium-pilocarpine model (2017) (20)
- VIP: An Agent with License to Kill Infective Parasites (2006) (20)
- Research progress in the stimulatory inputs regulating growth hormone (GH) secretion. (2002) (20)
- Neuropeptides as therapeutic approach to autoimmune diseases. (2010) (20)
- Lulling immunity, pain, and stress to sleep with cortistatin (2015) (19)
- VIP and PACAP Enhance the In Vivo Generation of Memory TH2 Cells by Inhibiting Peripheral Deletion of Antigen-Specific Effectors (2001) (18)
- Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency. (2016) (18)
- Hypophagia and induction of serotonin transporter gene expression in raphe nuclei of male and female rats after short-term fluoxetine treatment (2013) (17)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Endotoxin-Induced TNF-α Production by Macrophages: In Vitro and In Vivo Studies (1999) (16)
- The neuropeptide cortistatin attenuates experimental autoimmune myocarditis via inhibition of cardiomyogenic T cell‐driven inflammatory responses (2017) (16)
- [18F]FDG PET Neuroimaging Predicts Pentylenetetrazole (PTZ) Kindling Outcome in Rats (2016) (16)
- Anti‐inflammatory Actions of VIP/PACAP: Role in Endotoxemia (2000) (16)
- Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Inhibit Endotoxin-Induced TNF-a Production by Macrophages : In Vitro and In Vivo Studies 1 (1999) (15)
- Design and synthesis of S-(-)-2-[[4-(napht-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2-a]pyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist. (2003) (14)
- Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD 4 and CD 8 regulatory T cells (2006) (14)
- Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis (2018) (13)
- Vasoactive Intestinal Polypeptide Induces Regulatory Dendritic Cells That Prevent Acute Graft Versus Host Disease and Leukemia Relapse after Bone Marrow Transplantation (2006) (13)
- Use of 11C-(+)-α-dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease (2008) (13)
- VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4+ T cells (2001) (13)
- Vasoactive intestinal peptide generates CD4CD25 regulatory T cells in vivo (2005) (12)
- Effect of adrenaline and glucocorticoids on monocyte cAMP-specific phosphodiesterase (PDE4) in a monocytic cell line (2002) (12)
- Peritonitis in continuous ambulatory peritoneal dialysis: cytokines in peritoneal fluid and blood. (2002) (11)
- [Use of 11C-(+)-alpha -dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease]. (2008) (11)
- Cortistatin as a potential multistep therapeutic agent for inflammatory disorders. (2006) (11)
- A longitudinal FDG-PET study of transgenic mice overexpressing GSK- 3β in the brain. (2014) (11)
- Vasoactive intestinal peptide family as a therapeutic target for Parkinson’s disease (2005) (11)
- Peripheral nerve reconstruction with epsilon-caprolactone conduits seeded with vasoactive intestinal peptide gene-transfected mesenchymal stem cells in a rat model (2014) (10)
- Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats. (2017) (10)
- Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. (2017) (10)
- Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity (2020) (10)
- Serotonin Depletion Does not Modify the Short-Term Brain Hypometabolism and Hippocampal Neurodegeneration Induced by the Lithium–Pilocarpine Model of Status Epilepticus in Rats (2016) (10)
- Secretory Plasticity of Pituitary Cells: A Mechanism of Hormonal Regulation (2002) (10)
- Inhibition of Interferon (IFN) γ-induced Jak-STAT1 Activation in Microglia by Vasoactive Intestinal Peptide (2003) (9)
- VIP Protects Th2 Cells by Downregulating Granzyme B Expression (2006) (9)
- Longitudinal assessment of a transgenic animal model of tauopathy by FDG-PET imaging. (2014) (9)
- Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis (2015) (9)
- Structure-based design of a Cortistatin analogue with immunomodulatory activity in models of inflammatory bowel disease (2021) (8)
- N-(4-[(18)F]-fluoropyridin-2-yl)-N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}carboxamides as analogs of WAY100635. New PET tracers of serotonin 5-HT(1A) receptors. (2014) (8)
- Therapeutic application of mesenchymal stromal cells in murine models of inflammatory bowel disease. (2014) (8)
- Silyl resveratrol derivatives as potential therapeutic agents for neurodegenerative and neurological diseases. (2021) (8)
- Cytokines and peritonitis in continuous ambulatory peritoneal dialysis: immunodeviation and immunodeficiency. (2002) (7)
- Protective role of cortistatin in pulmonary inflammation and fibrosis (2021) (7)
- The atypical RhoGTPase RhoE/Rnd3 is a key molecule to acquire a neuroprotective phenotype in microglia (2018) (7)
- Role of Cortistatin in the Stressed Immune System. (2017) (7)
- Survival on chronic dialysis: 10 years' experience of a single Colombian center. (2005) (7)
- Vasoactive Intestinal Peptide ( VIP ) and Pituitary Adenylate Cyclase-Activation Polypeptide ( PACAP ) Protect Mice from Lethal Endotoxemia Through the Inhibition of TNF-a and IL-61 (1998) (6)
- Correction: LABCG2, a New ABC Transporter Implicated in Phosphatidylserine Exposure, Is Involved in the Infectivity and Pathogenicity of Leishmania (2013) (6)
- Ghrelin and adipose-derived mesenchymal stromal cells improve nerve regeneration in a rat model of epsilon-caprolactone conduit reconstruction. (2017) (6)
- Histamine up-regulates phosphodiesterase IV activity in U-937 cells through H2 receptor stimulation and cAMP increase. (2003) (6)
- Macrophages : In Vitro and In Vivo Studies Enhance IL-10 Production by Murine Adenylate Cyclase-Activating Polypeptide Vasoactive Intestinal Peptide and Pituitary and Doina Ganea (1999) (5)
- Metyrapone prevents acute glucose hypermetabolism and short-term brain damage induced by intrahippocampal administration of 4-aminopyridine in rats (2018) (5)
- Biochemical, Electrophysiological and Neurohormonal Studies with B-20991, a Selective 5-HT1A Receptor Agonist (2001) (5)
- Preliminary research on 1-(4-bromo-2-nitroimidazol-1-yl)-3-[(18)F]fluoropropan-2-ol as a novel brain hypoxia PET tracer in a rodent model of stroke. (2015) (5)
- Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes , sst 1 , sst 2 and sst 5 mRNA (2004) (4)
- Modulation of B7.1 and B7.2 Expression Activated Macrophages Through the Costimulatory Activity of Resting and VIP and PACAP Differentially Regulate the (1999) (4)
- In Vivo [18F] FDG PET Imaging Reveals that p-Chloroamphetamine Neurotoxicity is Associated with Long-Term Cortical and Hippocampal Hypometabolism (2015) (4)
- arthritisregulatory T cells in vitro in rheumatoid reduce inflammatory and T-cell responses and Human adipose-derived mesenchymal stem cells (2009) (4)
- Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors. (2005) (4)
- Expression of Membrane Melatonin Receptor mRNA in Rat Thymus and Spleen (1997) (3)
- The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury (2021) (3)
- Human bone marrow mesenchymal stem cells lose immunosuppressive and anti-inflammatory properties upon oncogenic transformation (2014) (3)
- Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic‐ and cholestatic‐induced liver injury (2021) (3)
- Potential applications of vasoactive intestinal Peptide-based therapies on transplantation. (2012) (3)
- Preliminary performance evaluation of a high resolution small animal PET scanner with monolithic crystals and depth-of-interaction encoding (2008) (3)
- Neuropeptide Cortistatin Regulates Dermal and Pulmonary Fibrosis in an Experimental Model of Systemic Sclerosis (2021) (2)
- Vasoactive Intestinal Peptide: Immune Mediator and Potential Therapeutic Agent (2012) (2)
- Vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide and immune system: from basic research to potential clinical application (2001) (2)
- Computational Simulation of Ligand-Receptor Interaction of 5-HT 1 AR Agonists with Selectivity over r 1-Adrenoceptors (2)
- Cortistatin, a new antiinfl ammatory peptide with therapeutic eff ect on lethal endotoxemia (2006) (2)
- Switching Roles: Beneficial Effects of Adipose Tissue-Derived Mesenchymal Stem Cells on Microglia and Their Implication in Neurodegenerative Diseases (2022) (2)
- Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide as modulators of innate and adaptive immunity (2008) (1)
- Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis (2020) (1)
- Adenylate Cyclase-Activating Polypeptide by Vasoactive Intestinal Peptide and Pituitary Kinase-1-STAT1 Activation in Macrophages -Induced Janus g Inhibition of IFN-Mario (2000) (1)
- The atypical RhoGTPase RhoE/Rnd3 is a key molecule to acquire a neuroprotective phenotype in microglia (2018) (1)
- Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell (2022) (1)
- Therapeutic approaches of vasoactive intestinal peptide as an immunomodulatory cytokine (2004) (1)
- Immunobiology of the Pituitary Adenylate Cyclase-Activating Peptide (2016) (0)
- VIP and PACAP Immune Mediators Involved in Homeostasis and Disease (2004) (0)
- Construction of different radionuclide templates of rat brains and their use on a new SPM analysis protocol for PET studies (2010) (0)
- Activation B and IFN Regulatory Factor 1 κ NF-Transcription in Macrophages by Inhibiting Prevent Inducible Nitric Oxide Synthase Adenylate Cyclase-Activating Polypeptide Vasoactive Intestinal Peptide and Pituitary and Doina Ganea (1999) (0)
- CellsPeptide Generates Tolerogenic Dendritic The Neuropeptide Vasoactive Intestinal (2005) (0)
- Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions (2011) (0)
- Neuropeptide regulation of microglial function (2008) (0)
- Construction of different radionuclide templates of rat brains and their use on a new statistic parametric mapping analysis protocol for PET studies. | International WorkshopCNA´10: Bio-medical applications of Micro-PET (20-21 September 2010. Sevilla, Spain) (2010) (0)
- This information is current as Inhibiting Fas Ligand Expression Inhibit T Cell-Mediated Cytotoxicity by Adenylate Cyclase-Activating Polypeptide Vasoactive Intestinal Peptide and Pituitary (2017) (0)
- The progression of dopaminergic depletion in unilateral 6-OHDA-lesioned rats: PET imaging and histopathologic studies. | 8th FENS Forum of Neuroscience (14-18 July 2012. Barcelona, Spain) (2012) (0)
- Editorial: The innate immune system in rheumatoid arthritis (2022) (0)
- Up-Regulating B 7 . 2 Expression Stimulate the Induction of Th 2 Responses by Adenylate Cyclase-Activating Polypeptide Vasoactive Intestinal Peptide and Pituitary Ganea (1999) (0)
- Subject Index Vol. 62, 2001 (2001) (0)
- Correction to: The atypical RhoGTPase RhoE/Rnd3 is a key molecule to acquire a neuroprotective phenotype in microglia (2019) (0)
- Monoaminergic and metabolic Positron Emission Tomography of unilateral and bilateral 6-OHDA rat models of Parkinson's disease: a longitudinal in-vivo study. | 15º Congreso Nacional de laSociedad Española de NeuroCiencia (25-27 de Septiembre de 2013. Oviedo, Spain) (2013) (0)
- Studiesby Macrophages : In Vitro and In Vivo Production α Inhibit Endotoxin-Induced TNF-Adenylate Cyclase-Activating Polypeptide Vasoactive Intestinal Peptide and Pituitary (1999) (0)
- Growth Factors 2 / 3 B , κ T Lymphocytes by Regulating c-Myc , NF-Inhibit Expression of Fas Ligand in Activated Adenylate Cyclase-Activating Polypeptide Vasoactive Intestinal Peptide and Pituitary (2000) (0)
- Role of Neuropeptides in T-Cell Differentiation (2004) (0)
- CHAPTER 5 – Vasoactive Intestinal Peptide: An Anti-inflammatory Neuropeptide (2007) (0)
- The neuropeptide cortistatin induces cell death by autophagy in leukemic tumour cells (2010) (0)
- Bone marrow mesenchymal stem cells from aplastic anemia patients preserve functional and immune properties and do not contribute to the pathogenesis of the disease (2014) (0)
- Neuropeptides and immune tolerance: Therapeutic applications on autoimmunity and transplantation (2006) (0)
- and IL-6 a of TNF-Lethal Endotoxemia Through the Inhibition Polypeptide (PACAP) Protect Mice from Pituitary Adenylate Cyclase-Activation Vasoactive Intestinal Peptide (VIP) and (1998) (0)
- Peptide a Type 2 Cytokine? Cutting Edge: Is Vasoactive Intestinal (2001) (0)
- Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Commentary (2006) (0)
- Comparison of immunophenotypes in the blood of patients on continuous ambulatory peritoneal dialysis, asymptomatic and with peritonitis. (2002) (0)
- Structure-based design of a Cortistatin analog with improved immunoregulatory activity against inflammatory bowel disease (IBD) (2019) (0)
- Decreased glucose-derivate uptake in primary somatosensorial cortex in the brain of female AIP mice. | International Porphyrins and Porphyria Meeting (10-13 April 2011. Cardiff, Wales, UK) (2011) (0)
- VIP and PACAP inhibit endotoxin-induced TNFa production in macrophages (1998) (0)
- Therapeutic Effect of a Latent Form of Cortistatin in Experimental Inflammatory and Fibrotic Disorders (2022) (0)
- P-2: Cortistatin, a new anti-inflammatory neuropeptide with therapeutic application on immune disorders (2006) (0)
- Transcription in Macrophages by Inhibiting Prevent Inducible Nitric Oxide Synthase Adenylate Cyclase-Activating Polypeptide Vasoactive Intestinal Peptide and Pituitary (1999) (0)
- ExpressionT Lymphocytes by Inhibiting Fas Ligand Inhibit Antigen-Induced Apoptosis of Mature Adenylate Cyclase-Activating Polypeptide Vasoactive Intestinal Peptide and Pituitary (2000) (0)
- Cyclase-Activating Polypeptide In Vitro and Intestinal Peptide and Pituitary Adenylate Chemokine Production by Vasoactive Inhibition of Endotoxin-Induced Macrophage (2001) (0)
- VIP and PACAP inhibit endotoxin-induced TNFa production by macrophages (1998) (0)
- Hypophagia and induction of serotonin transporter gene expression in raphe nuclei of male and female rats after short-term fluoxetine treatment (2012) (0)
- Contents Vol. 62, 2001 (2001) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mario Delgado?
Mario Delgado is affiliated with the following schools:
